MI sectors covered are:
• Nuclear Imaging
• Near infrared or optical imaging
• Tracers and Radiopharmaceuticals
Past News ReleasesRSS
Dallas, Texas (PRWEB) April 10, 2013
Since 2010, the market has seen stronger growth, helped by demand in under-penetrated markets, the adoption of newer-generation hybrid imaging technologies such as PET/CT and a move towards the use of PET from SPECT, necessitating the purchase of new PET systems.
The short-lived positron-emitting isotopes used in PET imaging are generally produced in a cyclotron and then synthesised on-site before patient administration. Although not requiring the use of a nuclear reactor, this limits the use of PET imaging to centres with access to a cyclotron and synthesis equipment. Therefore, a major development is the recent availability of smaller and cheaper cyclotrons which are designed to produce C-11 and F-18 isotopes economically and on-demand, without the need for radiochemistry or PET accelerator expertise.
The drive towards PET has been additionally boosted by advancement in the diagnosis of Alzheimer’s disease and the approval of Avid Radiopharmaceuticals’ Amyvid (florbetapir F-18 injection). Avid (owned by Eli Lilly) is the first company to achieve approval for a diagnostic PET tracer which estimates beta amyloid neuritic plaque density in adults with cognitive impairment. This is likely to become a busy marketplace with GE, Piramel and Navidea developing late-stage products whilst the focus of new research is targeting the tau proteins.
With this report one will:
- Know the state of the molecular imaging market (http://www.reportsnreports.com/reports/232986-advances-in-molecular-imaging-a-market-coming-of-age.html) and recent advances in Alzheimer’s diagnosis
- Establish the future market growth with 5-year value forecasts
- Know the clinical and regulatory challenges facing the sector
- Assess the companies that are developing hybrid technologies
- Review the challenges facing producers of radiopharmaceuticals and the research which is seeking alternative paths
- Know why PET is outpacing SPECT and the advantages it brings
- Appreciate the regulatory hurdles affecting radiopharmaceutical producers in the US
- Understand the changing competitive landscape and market positioning of new entrants
In particular, the increasing incidence of cancer, cardiovascular and neurological diseases means that demand for faster and more accurate diagnosis, as well as drug development and pre-clinical study efforts, will continue to accelerate in coming years. In addition, MI technologies will become more widely adopted as clinical evidence is established as to their benefits, and new technological innovations continue to be brought to market, particularly related to the MI of cancer and neurological diseases such as Alzheimer’s and Parkinson’s.
In addition, the current lack of penetration for nuclear and molecular imaging in emerging economies is driving demand, where new facilities are being set up and lower-cost systems are in demand.
The report covers companies active in the major MI sectors: Nuclear Imaging, Near infrared or optical imaging, Ultrasound, MRI, MRI/PET, MRI/SPECT, Tracers and Radiopharmaceuticals
Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=232986.
Global Markets and Technologies for Molecular, Nanoscale and Atomic Imaging (http://www.reportsnreports.com/reports/231727-global-markets-and-technologies-for-molecular-nanoscale-and-atomic-imaging.html) - This report provides:
- An overview of the global market for molecular, nanoscale, and atomic imaging.
- Analyses of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017.
- Descriptions of imaging equipment and technologies for examining materials, electronics, and biological samples.
- Coverage of technological issues, including novel molecular, nanometer, and atomic imaging capabilities.
- Examination of research activities and areas of interest related to imaging applications.
- Comprehensive company profiles of major players.
Molecular Diagnostics: Technologies and Global Markets (http://www.reportsnreports.com/reports/228242-molecular-diagnostics-technologies-and-global-markets.html) - This report provides:
- An overview of the global market for molecular diagnostics.
- Analyses of global market trends, with data from 2010 through 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Discussion of related issues, such as government regulation, reimbursement through insurance, patient confidentiality, and other legal ramifications.
- Identification of scientific challenges and advances, including the latest trends.
- Comprehensive company profiles and a patent analysis.
Molecular Diagnostics in Cancer Testing (http://www.reportsnreports.com/reports/75216-molecular-diagnostics-in-cancer-testing.html) – This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for cancer. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of cancer. This report analyzes the size and growth of the molecular diagnostics market in its applications for cancer detection and therapy, examining the factors that influence the various market segments and the dollar volume of sales, both in the United States and worldwide.
ReportsnReports.com is an online market research reports library of 200,000+ reports and in-depth studies of 5000+ micro markets.